Brian Halak, Ph.D., Partner
Brian joined Domain in 2001 and became a partner in 2006. He has been involved with new company creation and in establishing and directing Domain’s new initiative in China in collaboration with Beijing Elite.
I enjoy venture investment because of the excitement of looking at new technologies and imagining what they might become as products and businesses.
Present board memberships include Alimera Sciences, BioNano Genomics, Dicerna Pharmaceuticals, Kona Medical, Zyga Technology and WindMIL Therapeutics, where he is also acting President and CEO. He previously served on the boards of Eddingpharm, Esprit Pharma (until acquired by Allergan), GI Dynamics, Tobira Therapeutics, and Vanda Pharmaceuticals.
Prior to Domain, Brian was an associate with Advanced Technology Ventures where he participated in the firm’s investments in Plexxikon, Percardia and Emphasys. Previous to that, he was a consultant at the Wilkerson Group, where he developed strategy for pharmaceutical and medical device companies. Brian received his BSE in bioengineering from University of Pennsylvania and his Ph.D. in immunology from Thomas Jefferson University.
Brian is currently a member of the Advisory Board for the Department of BioEngineering of the University of Pennsylvania, an advisor to Elm Street Ventures, and a director on the board of Pennsylvania BIO.